| Business Summary | | Ostex
International,
Inc.
is
engaged
in
the
discovery
and
commercialization
of
products
associated
with
osteoporosis
and
other
collagen-related
diseases.
The
Company
believes
that
its
lead
product,
the
OSTEOMARK
test,
now
available
in
multiple
test
formats,
incorporates
patented
technology
in
the
area
of
bone
resorption
measurement.
The
Company
is
the
exclusive
licensee
of
the
Osteomark
technology,
known
clinically
as
the
NTx
test,
which
is
available
in
multiple
formats
that
can
aid
in
healthcare
decision-making
at
early
menopause
and
beyond.
The
Osteomark
test
is
a
non-invasive
test
that
quantitatively
indicates
the
level
of
bone
resorption.
In
addition,
the
Company's
Osteomark
test
aids
clinicians
in
monitoring
the
effects
of
antiresorptive
therapies
in
postmenopausal
women
and
those
diagnosed
with
osteoporosis,
in
a
matter
of
three
months
versus
one
to
two
years
with
conventional
technology. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Ostex
International,
Inc.
is
engaged
in
the
discovery
and
commercialization
of
products
associated
with
osteoporosis
and
other
collagen-related
diseases.
For
the
six
months
ended
6/30/01,
total
revenues
rose
23%
to
$3
million.
Net
loss
rose
9%
to
$1.4
million.
Revenues
reflect
increased
shipments
of
NTx
Serum
kits
and
Urine
kits.
Higher
loss
reflects
cost
associated
with
inventory
adjustments
and
costs
associated
with
the
NTx
Point
of
Care
device. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Thomas Bologna, 52 Chairman,
Pres, CEO | $466K | Thomas Broderick, 52 VP,
Patent and Gen. Counsel | 195K | Michael Perry, 56 VP
of Sales and Marketing | 115K | J. Daniel Clemens, 44 VP,
Product Devel. | 122K | Nancy Mallinak, 39 VP,
Regulatory and Clinical Affairs | 119K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|